Management of Mid-Rectal Cancer

Moderator(s)

• 

  Seth Felder, MD

  Colon and Rectum Surgeon
  H. Lee Moffitt Cancer Center and Research Institute, United States

  Disclosure(s): No financial relationships to disclose

Rapid advances in the field of rectal cancer along with changing patient demographics make the management of the mid-rectal tumor challenging. This session will review the results of the OPRA and PROSPECT trials, the treatment of mismatch-repair-deficient cancers, and special considerations for young adults and patients with inflammatory bowel disease.

Presentations:

• 11:20am – 11:30am ET

  OPRA vs. PROSPECT – Should you Omit Surgery or Radiation for MMR-intact Cancers?
  

  Presenter: Karyn Stitzenberg, MD, MPH (she/her/hers) – University of North Carolina
• 11:30am – 11:40am ET

  Mismatch-repair Deficient Cancers
  

  Presenter: Olatunji Alese, MD – Winship Cancer Institute of Emory University
• 11:40am – 11:50am ET

  What to do in the Setting of Inflammatory Bowel Disease for MMR-deficient and MMR-intact Cancers
  

  Presenter: Patrick Sullivan, BS, MD (he/him/his) – Emory University, Winship Cancer Institute
• 11:50am – 12:00pm ET

  Special Considerations for Young Adult Patients
  

  Presenter: Nicole Lopez, MD (she/her/hers) – UC San Diego
• 12:00pm – 12:20pm ET

  Questions & Discussion